Gene/NN
Expression/NN
Analysis/NN
of/IN
Megakaryocytes/NNS
Derived/JJ
from/IN
Human/JJ
Umbilical/JJ
Cord/NN
CD34/NN
+/JJ
Cells/NNS
by/IN
Thrombopoietin/NN
./.
====================
Although/IN
much/JJ
is/VBZ
known/VBN
about/IN
the/DT
molecular/JJ
biology/NN
of/IN
====================
platelets/NNS
,/,
the/DT
megakaryocytes/NNS
'/``
(/(
MKs/NNS
)/)
molecular/JJ
biology/NN
was/VBD
not/RB
understood/VBN
so/RB
well/RB
because/IN
of/IN
their/PRP$
rareness/JJ
./.
====================
By/IN
the/DT
cloning/NN
and/CC
characterization/NN
of/IN
thrombopoietin/NN
(/(
TPO/NN
)/)
,/,
which/WDT
is/VBZ
the/DT
principal/JJ
regulator/NN
of/IN
the/DT
growth/NN
and/CC
development/NN
of/IN
the/DT
MKs/NNS
,/,
researches/VBZ
on/IN
the/DT
MKs/NNS
have/VBP
been/VBN
growing/VBG
rapidly/RB
./.
====================
To/TO
understand/VB
megakaryocytopoiesis/NN
,/,
we/PRP
investigated/VBD
the/DT
gene/NN
expression/NN
profile/NN
of/IN
the/DT
MKs/NNS
using/VBG
oligonucleotide/JJ
microarray/NN
where/WRB
10,108/CD
unique/JJ
genes/NNS
were/VBD
spotted/VBN
./.
====================
Comparing/VBG
the/DT
fluorescence/NN
intensities/NNS
of/IN
which/WDT
ratio/NN
is/VBZ
>/JJR
|2|/CD
,/,
372/CD
genes/NNS
were/VBD
up-regulated/VBN
and/CC
541/CD
genes/NNS
were/VBD
down-regulated/VBN
in/IN
MKs/NNS
./.
====================
For/IN
confirmatory/JJ
expression/NN
,/,
RNase/NN
protection/NN
assay/NN
(/(
RPA/NN
)/)
establishing/VBG
abundant/JJ
apoptotic/JJ
gene/NN
expression/NN
was/VBD
carried/VBN
out/RP
./.
====================
In/IN
MKs/NNS
,/,
many/JJ
of/IN
the/DT
known/JJ
genes/NNS
,/,
including/VBG
several/JJ
platelet/NN
related/JJ
genes/NNS
,/,
GATA/NN
binding/NN
protein/NN
were/VBD
highly/RB
expressed/VBN
./.
====================
Particularly/RB
,/,
TGF/NN
beta/NN
,/,
clusterin/NN
(/(
complement/NN
lysis/NN
inhibitor/NN
)/)
,/,
and/CC
thymosin/NN
beta/NN
====================
4/CD
(/(
actin-sequestering/VBG
molecules/NNS
)/)
were/VBD
expressed/VBN
highly/RB
in/IN
MKs/NNS
./.
====================
As/IN
MKs/NNS
specific/JJ
expressed/VBN
genes/NNS
may/MD
regulate/VB
normal/JJ
and/CC
pathologic/JJ
platelet/NN
(/(
and/or/CC
MK/NN
)/)
functions/VBZ
,/,
the/DT
transcript/NN
profiling/VBG
using/VBG
microarray/NN
was/VBD
useful/JJ
on/IN
molecular/JJ
understanding/NN
of/IN
MKs/NNS
,/,
====================
While/IN
megakaryocyte/NN
(/(
MK/NN
)/)
plays/VBZ
critical/JJ
roles/NNS
as/IN
a/DT
reservoir/NN
of/IN
platelets/NNS
,/,
the/DT
process/NN
of/IN
differentiation/NN
and/CC
====================
platelet/NN
formation/NN
is/VBZ
not/RB
yet/RB
illustrated/JJ
(/(
Tao/NN
eta/./FW
,/,
1999/CD
;/:
Falcieri/NNP
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
The/DT
major/JJ
limiting/VBG
factor/NN
in/IN
investigating/VBG
the/DT
process/NN
of/IN
megakaryocytopoiesis/NN
is/VBZ
the/DT
low/JJ
frequency/NN
of/IN
MKs/NNS
in/IN
hematopoietic/JJ
tissues/NNS
./.
====================
The/DT
discovery/NN
and/CC
cloning/VBG
of/IN
thrombopoietin/NN
(/(
TPO/NN
)/)
,/,
which/WDT
can/MD
differentiate/VB
hematopoietic/JJ
stem/NN
cells/NNS
to/TO
MKs/NNS
,/,
has/VBZ
provided/VBN
the/DT
sufficient/JJ
number/NN
of/IN
cells/NNS
for/IN
the/DT
further/JJ
study/NN
of/IN
MKs/NNS
(/(
Piacibello/NN
et/FW
al./FW
,/,
1997/CD
)/)
./.
====================
TPO/NN
is/VBZ
the/DT
primary/JJ
regulator/NN
of/IN
megakaryocytopoiesis/NN
and/CC
thrombopoiesis/NN
./.
====================
TPO/NN
supports/VBZ
the/DT
differentiation/NN
and/CC
proliferation/NN
of/IN
MK/NN
progenitor/NN
cells/NNS
,/,
and/CC
has/VBZ
an/DT
essential/JJ
role/NN
for/IN
the/DT
complete/JJ
maturation/NN
of/IN
MKs/NNS
./.
====================
TPO/NN
also/RB
supports/VBZ
the/DT
formation/NN
and/CC
the/DT
function/NN
of/IN
platelets/NNS
in/IN
vivo/FW
and/CC
in/IN
vitro/FW
./.
====================
For/IN
the/DT
comprehensive/JJ
analysis/NN
of/IN
transcript/NN
expression/NN
,/,
the/DT
array-based/VBN
hybridization/NN
analysis/NN
and/CC
the/DT
serial/JJ
analysis/NN
of/IN
gene/NN
expression/NN
(/(
SAGE/NN
)/)
are/VBP
commonly/RB
used/VBN
platforms/NNS
./.
====================
DNA/NN
microarray/NN
is/VBZ
a/DT
powerful/JJ
tool/NN
for/IN
monitoring/VBG
thousands/NNS
of/IN
transcript/NN
levels/NNS
,/,
but/CC
it/PRP
can/MD
detect/VB
only/RB
relative/JJ
expression/NN
level/NN
by/IN
competitive/JJ
hybridization/NN
(/(
Schena/NNP
eta/./FW
,/,
1995/CD
)/)
./.
====================
SAGE/NN
analysis/NN
is/VBZ
a/DT
high-throughput/JJ
sequencing-based/VBN
technique/NN
and/CC
the/DT
relative/JJ
abundance/NN
of/IN
transcripts/NNS
in/IN
the/DT
sample/JJ
can/MD
be/VB
estimated/VBN
because/IN
it/PRP
is/VBZ
able/JJ
to/TO
scale/VB
of/IN
the/DT
transcripts/NNS
by/IN
sequence/NN
tags/NNS
in/IN
the/DT
SAGE/NN
data/NNS
(/(
Velculescu/NNP
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
The/DT
microarray/NN
technique/NN
has/VBZ
some/DT
advantages/NNS
./.
====================
If/IN
using/VBG
high-density/JJ
microarray/NN
,/,
it/PRP
can/MD
profile/VB
several/JJ
thousands/NNS
of/IN
transcripts/NNS
,/,
simultaneously/RB
./.
====================
Previously/RB
,/,
we/PRP
have/VBP
performed/VBN
microSAGE/NNS
in/IN
MKs/NNS
and/CC
non-MKs/NNS
derived/VBN
from/IN
the/DT
human/JJ
umbilical/JJ
cord/NN
blood/NN
(/(
CB/NN
)/)
CD34+/JJ
cells/NNS
by/IN
ex/FW
vivo/FW
expansion/NN
using/VBG
TPO/NN
(/(
Kim/NN
eta/./FW
,/,
2002/CD
)/)
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
the/DT
gene/NN
expression/NN
profiles/NNS
of/IN
MKs/NNS
were/VBD
analyzed/VBN
by/IN
high-density/JJ
oligonucleotide/NN
microarray/NN
hybridization/NN
and/CC
RNase/NN
protection/NN
assay/NN
(/(
RPA/NN
)/)
was/VBD
used/VBN
to/TO
validate/VB
the/DT
microarray/NN
result/NN
./.
====================
The/DT
data/NNS
present/VBP
herein/RB
showed/VBD
that/IN
many/JJ
of/IN
the/DT
genes/NNS
differentially/RB
expressed/VBN
in/IN
MKs/NNS
and/CC
non-MKs/NNS
were/VBD
involved/VBN
in/IN
encoding/VBG
proteins/NNS
related/JJ
to/TO
apoptosis/NN
and/CC
intracellular/JJ
signaling/VBG
pathways/NNS
./.
====================
Human/JJ
umbilical/JJ
CB/NN
was/VBD
obtained/VBN
from/IN
the/DT
full-term/JJ
deliveries/NNS
with/IN
the/DT
informed/VBN
consent/NN
./.
====================
Mononuclear/JJ
cells/NNS
were/VBD
isolated/VBN
from/IN
CB/NN
using/VBG
Ficoll-Hypaque/JJ
(/(
density/NN
,/,
1.077/CD
;/:
Pharmacia/NN
Biotech/NNP
;/:
Upsalla/FW
,/,
Sweden/JJ
)/)
density/NN
====================
centrifugation/NN
./.
====================
The/DT
CD34/NN
+/CC
cell/NN
fraction/NN
was/VBD
positively/RB
isolated/VBN
using/VBG
an/DT
anti-CD34/NN
monoclonal/JJ
antibody/NN
conjugated/JJ
paramagnetic/JJ
bead/RB
(/(
Miltenyi/NNP
Biotech/NNP
;/:
Bergisch/DT
Gladbach/NN
,/,
Germany/NNP
)/)
and/CC
CD34/NN
progenitor/NN
cell/NN
isolation/NN
kit/NN
(/(
Miltenyi/NNP
Biotech/NNP
)/)
,/,
followed/VBN
twice/RB
by/IN
the/DT
MidiMACS/NN
system/NN
(/(
Miltenyi/NNP
Biotech/NNP
)/)
./.
====================
The/DT
purity/NN
of/IN
the/DT
selected/VBN
population/NN
was/VBD
verified/VBN
by/IN
flow/NN
cytometry/NN
with/IN
an/DT
anti-human/JJ
CD34/NN
+/CC
antibody/NN
conjugated/JJ
with/IN
fluorescein/NN
isothiocyanate/NN
(/(
FITC/NN
;/:
HPCA-2/NN
;/:
Becton/IN
Dickinson/NN
(/(
BD/NN
)/)
,/,
Mountain/NNP
View/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
Aliquots/NNS
of/IN
enriched/JJ
cells/NNS
were/VBD
checked/VBN
for/IN
purity/NN
and/CC
were/VBD
consistently/RB
greater/JJR
than/IN
95/CD
%/NN
./.
====================
The/DT
CD34/NN
+/JJ
cells/NNS
were/VBD
cultured/VBN
at/IN
a/DT
density/NN
of/IN
1.0/CD
x/NN
10/CD
5/CD
====================
cells/mÂ£/JJ
in/IN
serum-free/JJ
essential/JJ
media/NNS
supplemented/VBD
with/IN
bovine/JJ
serum/NN
albumin/NN
,/,
insulin/NN
,/,
and/CC
transferrin/NN
(/(
Stem/NN
Cell/NN
Technologies/NNS
;/:
Vancouver/RB
,/,
Canada/NN
)/)
./.
====================
The/DT
cultures/NNS
were/VBD
stimulated/VBN
with/IN
recombinant/JJ
human/JJ
TPO/NN
(/(
50/CD
ng/ml/NN
;/:
Kirin/NN
Brewery/NN
,/,
Maebashi/NNP
,/,
Japan/NNP
)/)
alone/RB
./.
====================
After/IN
10/CD
days/NNS
,/,
MK/NN
fraction/NN
was/VBD
separated/VBN
from/IN
non-MK/JJ
fraction/NN
using/VBG
an/DT
anti-CD61/JJ
monoclonal/JJ
antibody/NN
conjugated/JJ
paramagnetic/JJ
bead/RB
(/(
Miltenyi/NNP
Biotech/NNP
)/)
followed/VBN
twice/RB
by/IN
the/DT
MidiMACS/NN
system/NN
(/(
Miltenyi/NNP
Biotech/NNP
)/)
./.
====================
The/DT
purity/NN
of/IN
each/DT
separated/VBN
fraction/NN
was/VBD
verified/VBN
by/IN
flow-cytometry/NN
with/IN
a/DT
different/JJ
antibody/NN
reacting/VBG
with/IN
MKs/NNS
(/(
FTIC-conjugated/JJ
anti-human/JJ
CD41/NN
;/:
BD/NN
)/)
./.
)/)
./.
====================
Aliquots/NNS
of/IN
enriched/JJ
cells/NNS
were/VBD
checked/VBN
for/IN
purity/NN
and/CC
were/VBD
consistently/RB
greater/JJR
than/IN
95/CD
%/NN
./.
====================
Total/JJ
RNA/NN
was/VBD
prepared/VBN
from/IN
the/DT
separated/VBN
MK/NN
and/CC
non-MK/JJ
fractions/NNS
using/VBG
the/DT
TRIZOL/NN
(/(
Gibco/NN
BRL/NN
;/:
NY/NN
,/,
USA/NN
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
Total/JJ
RNA/NN
(/(
5//g/CD
)/)
was/VBD
converted/VBN
into/IN
double/JJ
stranded/JJ
cDNA/NN
using/VBG
the/DT
cDNA/NN
synthesis/NN
System/NN
(/(
Roche/NNP
)/)
using/VBG
====================
T7-/CD
(/(
dT/NN
)/)
2/CD
4/CD
primer/NN
./.
====================
The/DT
each/DT
cDNA/NN
was/VBD
purified/VBN
using/VBG
the/DT
====================
Rneasy/NN
kit/NN
(/(
Qiagen/NN
;/:
Valencia/NN
,/,
USA/NN
)/)
./.
====================
Each/DT
Cy3-/NN
(/(
MKs/NNS
)/)
,/,
or/CC
Cy5-/NN
(/(
non-MKs/NNS
)/)
labeled/VBN
cRNA/NN
was/VBD
synthesized/VBN
using/VBG
the/DT
Megascript/NN
T7/NN
kit/NN
(/(
Ambion/NN
;/:
Austin/NN
,/,
USA/NNP
)/)
,/,
using/VBG
Cy3-CTP/NN
and/CC
Cy5-CTP/NN
(/(
APB/NN
;/:
Uppsala/NNP
Sweden/JJ
)/)
./.
====================
The/DT
cRNA/NN
was/VBD
purified/VBN
using/VBG
the/DT
RNeasy/NN
./.
====================
The/DT
purified/VBN
15/zg/JJ
of/IN
each/DT
cRNA/NN
was/VBD
mixed/VBN
and/CC
fragmented/JJ
in/IN
the/DT
fragmentation/NN
buffer/NN
(/(
40/CD
mm/NN
Tris/NN
(/(
pH/NN
8.1/CD
)/)
,/,
100/CD
mm/NN
KOAc/NN
,/,
and/CC
30/CD
mm/NN
MgOAC/NN
)/)
by/IN
heating/VBG
to/TO
94C/JJ
for/IN
15/CD
min/NN
./.
====================
The/DT
fragmented/JJ
cRNA/NN
was/VBD
mixed/VBN
with/IN
the/DT
hybridization/NN
buffer/NN
containing/VBG
100/CD
mm/NN
MES/NNS
,/,
1/CD
m/NN
NaCI/NN
,/,
20/CD
mm/NN
EDTA/NN
and/CC
0.01/CD
%/NN
Tween/CD
20/CD
,/,
and/CC
hybridized/VBD
with/IN
MAGIC/NN
11-10/CD
K/NN
Oligo/JJ
Chip/NN
(/(
Macrogen/NN
;/:
Seoul/JJ
,/,
Korea/NN
)/)
for/IN
16/CD
h/NN
at/IN
42C/NN
./.
====================
All/DT
preparations/NNS
met/NN
Macrogen/NN
's/POS
recommended/VBN
criteria/NNS
for/IN
====================
use/NN
on/IN
their/PRP$
expression/NN
arrays/NNS
./.
====================
The/DT
arrays/NNS
were/VBD
then/RB
washed/VBD
and/CC
scanned/VBD
with/IN
the/DT
Array/NN
scanner/NN
(/(
APB/NN
)/)
./.
====================
Acquired/VBN
images/VBZ
were/VBD
processed/VBN
and/CC
analyzed/VBD
statistically/RB
for/IN
interpretation/NN
of/IN
analyzed/VBN
spot/NN
intensity/NN
results/NNS
using/VBG
Imagene/JJ
v4.1/NN
software/JJ
(/(
Roche/NNP
)/)
./.
====================
Non-/NN
biological/JJ
factors/NNS
that/WDT
may/MD
contribute/VB
to/TO
variability/NN
of/IN
data/NNS
were/VBD
minimized/VBN
using/VBG
global/JJ
normalization/scaling/VBG
with/IN
data/NNS
from/IN
all/DT
probes/NNS
sets/NNS
./.
====================
Each/DT
chip/NN
contains/VBZ
a/DT
total/JJ
of/IN
10,368/CD
elements/NNS
of/IN
which/WDT
10,108/CD
are/VBP
unique/JJ
genes//NN
clusters/NNS
./.
====================
The/DT
length/NN
of/IN
oligonucleotides/NNS
was/VBD
50-mer/JJ
./.
====================
The/DT
RNase/NN
protection/NN
assay/NN
was/VBD
performed/VBN
using/VBG
the/DT
mouse/NN
cell/NN
cycle/NN
regulator/NN
multiprobe/NN
template/NN
sets/NNS
,/,
hAPO-3/NN
,/,
hAPO-5C/NN
and/CC
Hck-4/NN
(/(
BD/NN
Biosciences/NNS
)/)
./.
====================
[/(
32/CD
P/NN
]/)
-UTP/NN
labeled/VBN
anti-sense/JJ
RNA/NN
probe/NN
was/VBD
synthesized/VBN
using/VBG
T7/NN
RNA/NN
polymerase/NN
,/,
and/CC
was/VBD
purified/VBN
by/IN
phenol/NN
chloroform/NN
extractions/NNS
and/CC
ethanol/NN
precipitation/NN
./.
====================
The/DT
purified/VBN
probe/NN
was/VBD
mixed/VBN
with/IN
3/zg/JJ
of/IN
total/JJ
RNA/NN
from/IN
MK/NN
and/CC
non-MK/JJ
cells/NNS
in/IN
the/DT
hybridization/NN
buffer/NN
and/CC
incubated/VBN
for/IN
16/CD
h/NN
at/IN
56Â°C/NN
./.
====================
Free/JJ
probe/NN
and/CC
single/JJ
stranded/JJ
RNA/NN
molecules/NNS
were/VBD
digested/VBN
with/IN
a/DT
mixture/NN
of/IN
RNase/NN
A/NN
./.
====================
The/DT
RNase/NN
protected/VBD
molecules/NNS
were/VBD
purified/VBN
and/CC
resolved/VBD
on/IN
a/DT
denaturing/VBG
polyacrylamide/NN
gel/NN
and/CC
dried/VBD
./.
====================
Autoradiographic/JJ
signal/NN
was/VBD
scanned/VBN
on/IN
a/DT
Gel/NN
Doc/NNP
analyzer/CC
(/(
Bio-Rad/NNP
)/)
,/,
and/CC
the/DT
signal/NN
intensity/NN
of/IN
each/DT
band/NN
was/VBD
using/VBG
the/DT
Quantity/NN
ONE/NN
version/NN
4.2/CD
(/(
Bio-Rad/NNP
)/)
and/CC
normalized/VBD
to/TO
the/DT
corresponding/JJ
GAPDH/NN
levels/NNS
./.
====================
To/TO
reduce/VB
individual/JJ
variation/NN
of/IN
gene/NN
expression/NN
,/,
we/PRP
obtained/VBD
CB/NN
from/IN
three/CD
volunteers/NNS
as/IN
described/VBN
our/PRP$
previous/JJ
report/NN
(/(
Kim/NN
etal./FW
,/,
2002/CD
)/)
./.
====================
The/DT
purified/VBN
CB/NN
CD34/NN
+/JJ
cells/NNS
were/VBD
cultured/VBN
in/IN
the/DT
serum-free/JJ
liquid/JJ
culture/NN
system/NN
stimulated/VBD
with/IN
TPO/NN
for/IN
10/CD
days/NNS
./.
====================
Under/IN
this/DT
condition/NN
,/,
MK/NN
fraction/NN
could/MD
be/VB
isolated/VBN
using/VBG
anti-CD61/JJ
antibody/NN
,/,
and/CC
the/DT
purified/VBN
CD61/NN
+/JJ
cells/NNS
had/VBD
the/DT
characteristic/JJ
MK/NN
morphology/NN
(/(
Ryu/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
The/DT
total/JJ
RNA/NN
prepared/VBN
from/IN
these/DT
MK/NN
and/CC
non-MK/JJ
fractions/NNS
were/VBD
processed/VBN
to/TO
microarray/NN
analysis/NN
./.
====================
The/DT
each/DT
purified/VBN
RNA/NN
was/VBD
used/VBN
for/IN
cRNA/NN
generation/NN
and/CC
hybridization/NN
to/TO
the/DT
MAGIC/NN
11-10/CD
K/NN
Oligo/JJ
Chip/NN
./.
====================
After/IN
the/DT
normalization/NN
of/IN
====================
the/DT
fluorescence/NN
intensities/NNS
,/,
8,889/CD
transcripts/NNS
were/VBD
obtained/VBN
./.
====================
The/DT
scatter/NN
plot/NN
that/DT
was/VBD
plotted/VBN
with/IN
Cy3/NN
and/CC
Cy5/NN
fluorescent/JJ
signal/NN
values/NNS
displayed/VBD
a/DT
quite/RB
dispersed/JJ
pattern/NN
in/IN
distribution/NN
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
Each/DT
dot/NN
represents/VBZ
a/DT
gene/NN
expressed/VBN
in/IN
these/DT
two/CD
fractions/NNS
./.
====================
Most/JJS
of/IN
the/DT
spots/NNS
gathered/VBD
around/IN
a/DT
45Â°/CD
diagonal/JJ
line/NN
,/,
====================
significant/JJ
difference/NN
in/IN
the/DT
expression/NN
level/NN
between/IN
the/DT
two/CD
fractions/NNS
was/VBD
found/VBN
in/IN
many/JJ
transcripts/NNS
./.
====================
Subsets/NNS
of/IN
genes/NNS
were/VBD
selected/VBN
based/VBN
on/IN
the/DT
differential/JJ
Cy5/Cy3/NN
expression/NN
ratios/NNS
that/DT
were/VBD
|2|/CD
in/IN
response/NN
./.
====================
Out/DT
of/IN
the/DT
spotted/JJ
genes/NNS
,/,
372/CD
genes/NNS
were/VBD
up-regulated/VBN
and/CC
541/CD
genes/NNS
were/VBD
down-regulated/VBN
in/IN
MKs/NNS
./.
====================
As/IN
shown/VBN
on/IN
the/DT
tables/NNS
,/,
we/PRP
addressed/VBD
each/DT
of/IN
these/DT
groups/NNS
separately/RB
./.
====================
We/PRP
included/VBD
accession/NN
numbers/NNS
,/,
a/DT
short/JJ
description/NN
of/IN
the/DT
gene/NN
function/NN
and/CC
a/DT
reference/NN
for/IN
each/DT
gene/NN
to/TO
a/DT
recent/JJ
review/NN
on/IN
the/DT
function/NN
of/IN
the/DT
corresponding/JJ
gene/NN
limited/JJ
MKs/NNS
./.
====================
Table/JJ
1/CD
through/IN
3/CD
show/VBP
the/DT
genes/NNS
differentially/RB
expressed/VBN
in/IN
MKs/NNS
and/CC
non-MKs/NNS
./.
====================
Table/JJ
1/CD
shows/VBZ
the/DT
increased/VBN
,/,
or/CC
decreased/VBD
top/NN
30/CD
transcripts/NNS
in/IN
MKs/NNS
compared/VBN
to/TO
those/DT
in/IN
non-MKs/NNS
./.
====================
The/DT
most/JJS
frequently/RB
increased/VBN
transcript/NN
was/VBD
identified/VBN
to/TO
be/VB
ATP-binding/JJ
cassette/JJ
transporter/NN
mrp8/NN
(/(
38.24-fold/RB
)/)
followed/VBN
by/IN
hspc159/NN
protein/NN
(/(
33.9-fold/RB
)/)
,/,
cytochrome/NN
p450/NN
,/,
subfamily/RB
====================
xxiv/DT
precursor/NN
(/(
23.7-fold/JJ
)/)
,/,
protocadherin/NN
gamma/NN
subfamily/NN
a/DT
,/,
11/CD
,/,
isoform/NN
1/CD
precursor/NN
(/(
17.4-fold/JJ
)/)
,/,
and/CC
so/RB
on/IN
./.
====================
The/DT
transcripts/NNS
increased/VBD
in/IN
MKs/NNS
could/MD
be/VB
classified/VBN
into/IN
several/JJ
groups/NNS
according/VBG
to/TO
the/DT
functional/JJ
relevance/NN
./.
====================
Table/JJ
2/CD
shows/VBZ
the/DT
transcripts/NNS
regulation-related/VBN
proteins/NNS
such/JJ
as/IN
GATA-binding/JJ
protein/NN
1/CD
(/(
globin/NN
transcription/NN
factor/NN
1/CD
)/)
,/,
transcription/NN
factor/NN
BMAL2/NN
,/,
partial/JJ
transcription/NN
factor/NN
sp3/NN
,/,
gata-3/NN
binding/VBG
protein/NN
(/(
g3b/NN
)/)
,/,
transcription/NN
factor/NN
19/CD
(/(
SC1/NN
)/)
(/(
TCF19/NN
)/)
,/,
transcription/NN
factor/NN
ap-2/NN
(/(
activating/VBG
enhancer/NN
binding/VBG
protein/NN
2/CD
,/,
nuclear/JJ
factor/NN
i/c/NN
(/(
ccaat-binding/VBG
transcription/NN
factor/NN
)/)
./.
====================
The/DT
transcripts/NNS
for/IN
metabolic/JJ
pathway/NN
related/JJ
proteins/NNS
are/VBP
cytochrome/NN
p450/NN
,/,
subfamily/RB
xxiv/NN
precursor/NN
,/,
arachidonate/NN
12-lipoxygenase/NN
./.
====================
The/DT
gene/NN
for/IN
protease/NN
and/CC
apoptosis/NN
related/JJ
genes/NNS
,/,
such/JJ
as/IN
mannan-binding/VBG
lectin/NN
serine/NN
protease/NN
1/CD
,/,
clusterin/NN
,/,
sentrin/sumo-specific/JJ
protease/NN
could/MD
be/VB
found/VBN
./.
====================
Table/JJ
3/CD
showes/VBZ
the/DT
MAP/NN
kinase/NN
related/JJ
genes/NNS
such/JJ
as/IN
map/erk/VBP
kinase/NN
kinase/NN
5/CD
,/,
mitogen-activated/JJ
protein/NN
====================
kinase/NN
13/CD
,/,
mitogen-activated/JJ
protein/NN
kinase/NN
6/CD
,/,
protein/NN
kinase/NN
c/NN
,/,
1/CD
and/CC
./.
====================
The/DT
surface/NN
marker/NN
proteins/NNS
,/,
such/JJ
as/IN
CD9/NN
,/,
and/CC
CD62P/NN
(/(
P/NN
selectin/NN
)/)
were/VBD
observed/VBN
(/(
not/RB
shown/VBN
)/)
./.
====================
The/DT
RPA/NN
was/VBD
carried/VBN
out/RP
wheather/IN
the/DT
expression/NN
profile/NN
from/IN
the/DT
microarray/NN
is/VBZ
consistent/JJ
with/IN
the/DT
conventional/JJ
RNA/NN
analysis/NN
strategies/NNS
./.
====================
We/PRP
used/VBD
probe/NN
set/NN
(/(
BD/NN
)/)
,/,
which/WDT
were/VBD
expressed/VBN
differentially/RB
in/IN
MKs/NNS
and/CC
non-MKs/NNS
./.
====================
Among/IN
the/DT
RPA/NN
probe/NN
sets/NNS
(/(
hAPO-5C/NN
,/,
hAPO-3/NN
)/)
,/,
cluserin/NN
,/,
TRADD/NN
and/CC
caspase/NN
8/CD
are/VBP
matched/VBN
with/IN
transcripts/NNS
on/IN
microarray/NN
./.
====================
Using/VBG
RPA/NN
assay/NN
,/,
selected/VBN
genes/NNS
were/VBD
evaluated/VBN
in/IN
MKs/NNS
and/CC
non-MKs/NNS
derived/VBN
from/IN
CBs/NN
of/IN
two/CD
other/JJ
volunteers/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
These/DT
results/NNS
validated/VBD
our/PRP$
expression/NN
profiles/NNS
from/IN
the/DT
microarray/NN
for/IN
MKs/NNS
and/CC
established/JJ
the/DT
general/JJ
expression/NN
profile/NN
of/IN
the/DT
identified/VBN
genes/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
the/DT
microarray/NN
technique/NN
was/VBD
employed/VBN
to/TO
understand/VB
comprehensively/RB
the/DT
properties/NNS
of/IN
transcripts/NNS
in/IN
MKs/NNS
derived/VBN
from/IN
the/DT
CB/NN
CD/NN
34/CD
+/JJ
cells/NNS
./.
====================
The/DT
isolated/VBN
CD/NN
34/CD
+/JJ
cells/NNS
were/VBD
expanded/VBN
with/IN
TPO/NN
./.
====================
Then/RB
,/,
these/DT
expanded/VBN
cells/NNS
were/VBD
separated/VBN
using/VBG
anti-CD61/JJ
antibody/NN
,/,
which/WDT
is/VBZ
known/VBN
as/IN
a/DT
marker/NN
of/IN
MKs/NNS
./.
====================
Approximately/RB
10/CD
thousands/NNS
of/IN
genes/NNS
expressed/VBN
in/IN
the/DT
MKs/NNS
were/VBD
analyzed/VBN
using/VBG
high/JJ
density/NN
oligonucleotide/NN
microarray/NN
./.
====================
Previously/RB
,/,
we/PRP
reported/VBD
global/JJ
gene/NN
expression/NN
of/IN
MKs/NNS
using/VBG
SAGE/NN
technique/NN
(/(
Kim/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
When/WRB
comparing/VBG
to/TO
SAGE/NN
technology/NN
,/,
the/DT
microarray/NN
method/NN
has/VBZ
some/DT
advantages/NNS
,/,
such/JJ
as/IN
====================
simultaneity/NN
,/,
detection/NN
limit/VB
of/IN
low/JJ
expressed/VBN
genes/NNS
,/,
etc/NN
./.
====================
But/CC
,/,
it/PRP
is/VBZ
not/RB
easy/RB
to/TO
compare/VB
the/DT
transcription/NN
profiles/NNS
of/IN
the/DT
microarray/NN
with/IN
that/DT
of/IN
expression/NN
level/NN
of/IN
SAGE/NN
,/,
because/IN
of/IN
the/DT
different/JJ
bases/NNS
of/IN
the/DT
underlying/VBG
technology/NN
;/:
the/DT
competitive/JJ
hybridization/NN
of/IN
probes/NNS
vs./CC
the/DT
sequencing/NN
of/IN
ditags/NNS
./.
====================
Table/JJ
1/CD
shows/VBZ
the/DT
each/DT
top/NN
15/CD
transcripts/NNS
that/WDT
of/IN
expression/NN
levels/NNS
were/VBD
increased/VBN
or/CC
decreased/VBD
in/IN
MKs/NNS
and/CC
non-MKs/NNS
./.
====================
Many/JJ
transcription/NN
factors/NNS
related/JJ
MKs/NNS
====================
specific/JJ
gene/NN
expression/NN
were/VBD
reported/VBN
several/JJ
articles/NNS
(/(
Terui/NNP
etal./FW
,/,
2000/CD
;/:
Goodwin/NNP
etal./FW
,/,
2001/CD
;/:
Matsumura/NNP
et/FW
al./FW
,/,
1991/CD
)/)
;/:
nuclear/JJ
factor/NN
(/(
erythroid/JJ
derived/VBN
)/)
45/CD
kD/NN
,/,
cAMP/NN
responsive/JJ
element/NN
binding/VBG
protein-like/JJ
1/CD
,/,
erythroid/JJ
differentiation-related/JJ
factor/NN
1/CD
,/,
nuclear/JJ
factor/NN
(/(
erythroid-derived/JJ
2/CD
)/)
-like/JJ
1/CD
,/,
GATA1/NN
binding/VBG
protein/NN
,/,
etc/JJ
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
genes/NNS
encoding/VBG
GATA/NN
binding/NN
protein/NN
1/CD
and/CC
GATA/NN
3/CD
binding/NN
protein/NN
is/VBZ
highly/RB
expressed/VBN
in/IN
MKs/NNS
(/(
4.11/CD
and/CC
2.63/CD
fold/JJ
change/NN
;/:
Table/JJ
2/CD
)/)
./.
====================
GATA/NN
binding/NN
protein/NN
1/CD
is/VBZ
essential/JJ
for/IN
the/DT
development/NN
of/IN
megakaryocytic/JJ
and/CC
erythroid/JJ
lineages/NNS
(/(
Pevny/NN
ef/NN
al./FW
,/,
1991/CD
)/)
./.
====================
However/RB
,/,
some/DT
MKs/NNS
specific/JJ
transcription/NN
factors/NNS
,/,
such/JJ
as/IN
Kruppel-like/JJ
factor/NN
1/CD
(/(
erythroid/JJ
)/)
known/VBN
as/IN
GATA/NN
binding/NN
protein/NN
1/CD
binding/NN
partner/NN
,/,
erythroid/JJ
differentiation-related/JJ
factor/NN
1/CD
,/,
Nuclear/JJ
factor/NN
(/(
erythroid-derived/JJ
2/CD
)/)
-like/JJ
1/CD
,/,
sp1/NN
like/IN
transcription/NN
factor/NN
were/VBD
not/RB
detected/VBN
on/IN
microarray/NN
./.
====================
But/CC
these/DT
genes/NNS
of/IN
MKs/NNS
,/,
known/VBN
as/IN
specific/JJ
transcription/NN
factors/NNS
,/,
were/VBD
detected/VBN
in/IN
MKs/NNS
SAGE/NN
library/NN
./.
====================
This/DT
phenomenon/NN
induced/VBN
from/IN
limitation/NN
of/IN
microarray/NN
analysis/NN
because/IN
it/PRP
could/MD
analyze/VB
about/RB
finite/NN
number/NN
of/IN
gene/NN
sequences/NNS
localized/VBD
to/TO
the/DT
chip/NN
./.
====================
BMAL/NN
2/CD
was/VBD
expressed/VBN
highly/RB
in/IN
MKs/NNS
(/(
3.95/CD
fold/JJ
change/NN
)/)
./.
====================
The/DT
BMAL2/NN
gene/NN
encodes/VBZ
a/DT
member/NN
of/IN
the/DT
basic/JJ
helix-loop-helix/JJ
PER-ARNT-SIM/NN
(/(
bHLH-PAS/JJ
)/)
family/NN
of/IN
transcription/NN
factors/NNS
,/,
which/WDT
act/VBP
as/IN
transcription/NN
factor/NN
with/IN
CLOCK/NN
protein/NN
(/(
BMAL2/NN
:/:
CLOCK/NN
)/)
./.
====================
Its/PRP$
role/NN
in/IN
MKs/NNS
was/VBD
not/RB
reported/VBN
yet/RB
,/,
but/CC
it/PRP
is/VBZ
known/VBN
as/IN
the/DT
regulator/NN
of/IN
circadian/JJ
rhythm/NN
in/IN
brain/NN
(/(
Cohen/NNP
etal./FW
,/,
1997/CD
)/)
./.
====================
These/DT
up-regulated/VBD
transcription/NN
factors/NNS
,/,
such/JJ
as/IN
GATA/NN
related/JJ
genes/NNS
and/CC
BMAL2/NN
,/,
AP-2/NN
,/,
nuclear/JJ
factor/NN
i/c/NN
may/MD
influence/VB
MK-specific/JJ
gene/NN
expression/NN
directly/RB
./.
====================
In/IN
differentiation/NN
and/CC
maturation/NN
,/,
TPO/NN
primed/VBN
signaling/NN
====================
pathway/NN
is/VBZ
the/DT
major/JJ
process/NN
(/(
Miyazakiet/NN
etal./FW
,/,
2001/CD
)/)
./.
====================
Binding/NN
of/IN
TPO/NN
to/TO
its/PRP$
receptor/NN
,/,
c-Mpi/NN
,/,
results/VBZ
in/IN
the/DT
activation/NN
of/IN
a/DT
variety/NN
of/IN
signaling/VBG
molecules/NNS
,/,
which/WDT
included/VBD
components/NNS
of/IN
the/DT
Ras/MAPK/NN
pathway/NN
(/(
Fichelson/NN
et/FW
al./FW
,/,
2001/CD
)/)
,/,
and/CC
PKC/NN
pathway/NN
(/(
Jiang/NNP
et/FW
al./FW
,/,
2002/CD
;/:
Minamiguchi/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
the/DT
genes/NNS
encoding/VBG
proteins/NNS
related/JJ
to/TO
Ras/MAPK/NN
and/CC
PKC/NN
pathway/NN
,/,
such/JJ
as/IN
protein/NN
map/erk/VBP
kinase/NN
kinase/NN
5/CD
,/,
mitogen-activated/JJ
protein/NN
kinase/NN
6/CD
and/CC
13/CD
,/,
protein/NN
kinase/NN
c/NN
beta/NN
1/CD
and/CC
gamma/NN
etc/NN
were/VBD
expressed/VBN
highly/RB
in/IN
MKs/NNS
(/(
Table/JJ
3/CD
)/)
./.
====================
Tumor/NN
growth/NN
factor-/NN
(/(
TGF-/NN
)/)
related/JJ
protein/NN
,/,
such/JJ
as/IN
TGF-/NN
,/,
its/PRP$
receptor/NN
and/CC
binding/NN
partner/NN
,/,
were/VBD
up-regulated/VBN
in/IN
MKs/NNS
./.
====================
TGF-/NN
regulates/VBZ
cell/NN
growth/NN
,/,
differentiation/NN
,/,
and/CC
extracellular/JJ
matrix/NN
production/NN
./.
====================
The/DT
intracellular/JJ
signaling/VBG
of/IN
TGF-/NN
is/VBZ
initiated/VBN
following/VBG
ligand/NN
binding/NN
to/TO
the/DT
TGF-/NN
type/NN
II/CD
receptor/NN
,/,
which/WDT
activates/VBZ
TGF-/NN
type/NN
I/CD
receptor/NN
(/(
Kalina/NN
et/FW
al./FW
,/,
2001/CD
;/:
Massague/NN
,/,
1998/CD
)/)
./.
====================
The/DT
activated/VBN
type/NN
I/CD
receptor/NN
phosphorylates/VBZ
Smad/JJ
2/CD
and/CC
Smad/JJ
3/CD
,/,
resulting/VBG
in/IN
their/PRP$
translocation/NN
into/IN
the/DT
nucleus/NN
where/WRB
they/PRP
can/MD
bind/VB
to/TO
DNA/NN
in/IN
the/DT
promoters/NNS
of/IN
TGF-/NN
target/NN
genes/NNS
included/VBD
vascular/JJ
endothelial/JJ
growth/NN
factor/NN
(/(
VEGF/NN
)/)
(/(
Table/JJ
3/CD
)/)
(/(
Heldin/NN
et/FW
al./FW
,/,
1997/CD
;/:
Tokuda/NNP
etal./FW
,/,
2003/CD
)/)
./.
====================
But/CC
in/IN
our/PRP$
system/NN
,/,
Smad/NN
family/NN
was/VBD
not/RB
detected/VBN
on/IN
microarray/NN
./.
====================
In/IN
addition/NN
to/TO
the/DT
Smad/JJ
signaling/NN
pathway/NN
,/,
other/JJ
signaling/NN
pathways/NNS
such/JJ
as/IN
the/DT
mitogen-activated/JJ
protein/NN
(/(
MAP/NN
)/)
kinase/NN
superfamily/NN
have/VBP
recently/RB
been/VBN
shown/VBN
to/TO
mediate/VB
the/DT
TGF/NN
signaling/NN
pathway/NN
(/(
Hatakeyama/NN
etal./FW
,/,
2002/CD
)/)
./.
====================
MAPK/NN
pathway/NN
was/VBD
mediated/VBN
in/IN
TGF-/NN
signaling/NN
with/IN
Smad/JJ
pathway/NN
,/,
and/CC
PKC/NN
and/CC
MAPK/NN
pathway/NN
might/MD
influence/VB
each/DT
other/JJ
in/FW
platelet/NN
formation/NN
./.
====================
Interestingly/RB
,/,
thymosin/NN
beta/NN
4/CD
(/(
Th/NN
4/CD
)/)
was/VBD
up-regulated/VBN
====================
(/(
11.2-fold/JJ
)/)
and/CC
thymosin/NN
beta/NN
10/CD
(/(
Thw/NNP
)/)
was/VBD
down-/RB
regulated/VBN
(/(
7.28-fold/JJ
)/)
in/IN
MKs/NNS
./.
====================
Thymosin/DT
(/(
Th/NN
)/)
acts/VBZ
as/IN
the/DT
major/JJ
actin-sequestering/VBG
molecule/NN
in/IN
mammalian/JJ
cells/NNS
,/,
and/CC
is/VBZ
present/JJ
ubiquitously/RB
in/IN
most/JJS
tissues/NNS
and/CC
cell/NN
lines/NNS
and/CC
is/VBZ
found/VBN
in/IN
particularly/RB
high/JJ
concentrations/NNS
in/IN
blood/NN
platelets/NNS
,/,
neutrophils/NNS
,/,
macrophages/NNS
,/,
and/CC
other/JJ
lymphoid/JJ
cells/NNS
(/(
Hannappel/NNP
et/FW
al./FW
,/,
1982/CD
;/:
Huff/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
Thymosin/NN
beta/NN
4/CD
has/VBZ
been/VBN
reported/VBN
to/TO
prevent/VB
the/DT
cycling/NN
of/IN
hematopoietic/JJ
stem/NN
cells/NNS
(/(
Safer/NN
et/FW
al/JJ
./.
====================
,/,
1991/CD
)/)
,/,
to/TO
reduce/VB
the/DT
toxicity/NN
of/IN
cytosine/JJ
arabinoside/NN
,/,
to/TO
enhance/VB
the/DT
attachment/NN
and/CC
migration/NN
of/IN
endothelium/NN
(/(
Bonnet/NNP
et/FW
al./FW
,/,
1996/CD
)/)
,/,
and/CC
to/TO
induce/VB
production/NN
of/IN
metalloproteinases/NNS
(/(
Malinda/NN
etal./FW
,/,
1997/CD
)/)
./.
====================
Clusterin/NN
was/VBD
expressed/VBN
highly/RB
in/IN
MKs/NNS
(/(
4/CD
fold/JJ
change/NN
;/:
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Clusterin/NN
was/VBD
detected/VBN
highly/RB
in/IN
SAGE/NN
analysis/NN
in/IN
MKs/NNS
and/CC
platelets/NNS
(/(
Gnatenko/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Clusterin/NN
,/,
also/RB
known/VBN
as/IN
apolipoprotein/JJ
J/NN
(/(
Rosenberg/NNP
etal./FW
,/,
1995/CD
)/)
,/,
TRPM-2/NN
(/(
Wong/JJ
etal./FW
,/,
1993/CD
)/)
,/,
or/CC
SGP-2/NN
(/(
Jenne/NN
etal./FW
,/,
1992/CD
)/)
,/,
is/VBZ
an/DT
enigmatic/JJ
glycoprotein/NN
./.
====================
Its/PRP$
expression/NN
is/VBZ
widely/RB
distributed/VBN
in/IN
various/JJ
tissues/NNS
(/(
Trougakos/NNS
and/CC
Gonos./NNP
,/,
2002/CD
;/:
Jones/NNS
and/CC
Jomary/JJ
,/,
2002/CD
)/)
./.
====================
Previous/JJ
reports/NNS
have/VBP
correlated/VBN
clusterin/NN
expression/NN
with/IN
cell/NN
responses/NNS
to/TO
stress/NN
(/(
Poon/NN
et/FW
al./FW
,/,
2000/CD
)/)
,/,
cell/NN
damage/NN
recovery/RB
(/(
Bach/DT
et/FW
al./FW
,/,
2001/CD
)/)
,/,
senescence/NN
(/(
Wright/NNP
and/CC
Shay/NN
,/,
2001/CD
)/)
,/,
tumorigenesis/NN
and/CC
apoptosis/NN
(/(
Marinelli/NNP
etal./FW
,/,
1994/CD
)/)
./.
====================
Clusterin/NN
was/VBD
contained/VBN
in/IN
alpha/NN
granule/NN
which/WDT
is/VBZ
the/DT
largest/JJS
and/CC
most/JJS
abundant/JJ
secretary/JJ
granules/NNS
in/IN
platelets/NNS
(/(
Tschopp/NN
etai./FW
,/,
1993/CD
)/)
./.
====================
In/IN
summary/NN
,/,
we/PRP
identified/VBD
the/DT
genes/NNS
expressed/VBN
differentially/RB
in/IN
MKs/NNS
and/CC
non-MKs/NNS
derived/VBN
from/IN
human/JJ
CB/NN
CD34+/JJ
cells/NNS
by/IN
ex/FW
vivo/FW
expansion/NN
using/VBG
TPO/NN
./.
====================
The/DT
expression/NN
of/IN
several/JJ
genes/NNS
in/IN
signaling/VBG
molecule/NN
such/JJ
as/IN
,/,
RAS/MAPK/NN
,/,
PKC/NN
and/CC
TGF-/NN
related/JJ
genes/NNS
,/,
was/VBD
higher/JJR
in/IN
MKs/NNS
./.
====================
Interestingly/RB
,/,
the/DT
genes/NNS
coding/VBG
thymosin/NN
and/CC
clusterin/NN
were/VBD
highly/RB
expressed/VBN
in/IN
MKs/NNS
./.
====================
These/DT
gene/NN
expression/NN
data/NNS
from/IN
the/DT
microarray/NN
analysis/NN
may/MD
provide/VB
useful/JJ
information/NN
on/IN
MKs/NNS
differentiation/NN
,/,
maturation/NN
and/CC
platelet/NN
production/NN
./.
====================
